Targeting complement at the time of transplantation

Advances in Experimental Medicine and Biology

Volumn 734, Issue , 2013, Pages 247-255

  Sacks, Steven ^a,b   Karegli, Julia ^a,b   Farrar, Conrad A ^a,b   Asgari, Elham ^a,b   Schwaeble, Wilhelm ^c   Zhou, Wuding ^a,b   Smith, Richard A ^a,b  

^a GUY S HOSPITAL   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; COMPLEMENT; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5A; COMPLEMENT MEMBRANE ATTACK COMPLEX; HIRUDIN; IMMUNOGLOBULIN M; MIROCOCEPT; COMPLEMENT COMPONENT C3B RECEPTOR; RECOMBINANT PROTEIN;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; CELL INFILTRATION; CELL PROTECTION; CELL VIABILITY; COMPLEMENT ACTIVATION; CONFERENCE PAPER; CROSS PRESENTATION; DELAYED GRAFT FUNCTION; DENDRITIC CELL; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIUM; GRAFT SURVIVAL; HYPOXEMIA; KIDNEY ISCHEMIA; KIDNEY PROXIMAL TUBULE; KIDNEY TRANSPLANTATION; LIPID BILAYER; LONGEVITY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CLEAVAGE; PROTEIN DEPLETION; PROTEIN FUNCTION; REPERFUSION INJURY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; T LYMPHOCYTE; CLINICAL OUTCOME; COMPLEMENT DISORDER; COMPLEMENT SYSTEM; DRUG TARGETING; GRAFT REJECTION; HUMAN; INNATE IMMUNITY; RENAL ISCHEMIA REPERFUSION INJURY; RISK BENEFIT ANALYSIS; TREATMENT INDICATION;

EID: 84934438142     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-4118-2_17     Document Type: Conference Paper

References (51)

1. Botto M, Lissandrini D, Sorio C, Walport MJ (1992) Biosynthesis and secretion of complement component (C3) by activated human polymorphonuclear leukocytes. J Immunol 149:1348-13555
2. Colten HR, Ooi YM, Edelson PJ (1979) Synthesis and secretion of complement proteins by macrophages. Ann N Y Acad Sci 332:482-4900
3. Colvin RB, Smith RN (2005) Antibody-mediated organ-allograft rejection. Nat Rev Immunol 5:807-8177
4. Damman J, Seelen MA, Moers C, Daha MR, Rahmel A, Leuvenink HG, Paul A, Pirenne J, Ploeg RJ (2011a) Systemic complement activation in deceased donors is associated with acute rejection after renal transplantation in the recipient. Transplantation 92:163-1699
5. Damman J, Nijboer WN, Schuurs TA, Leuvenink HG, Morariu AM, Tullius SG, van Goor H, Ploeg RJ, Seelen MA (2011b) Local renal complement C3 induction by donor brain death is associated with reduced renal allograft function after transplantation. Nephrol Dial Transplant 26:2345-23544
6. de Vries B, Kohl J, Leclercq WK, Wolfs TG, van Bijnen AA, Heeringa P, Buurman WA (2003) Complement factor C5a mediates renal ischemia-reperfusion injury independent from neutrophils. J Immunol 170:3883-38899
7. Dempsey PW, Allison ME, Akkaraju S, Goodnow CC, Fearon DT (1996) C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271:348-3500
8. Dodd I, Mossakowska DE, Camilleri P, Haran M, Hensley P, Lawlor EJ, McBay DL, Pindar W, Smith RA (1995) Overexpression in Escherichia coli , folding, puri fication, and characterization of the first three short consensus repeat modules of human complement receptor type 1. Protein Expr Purif 6:727-7366
9. Farrar CA, Zhou W, Lin T, Sacks SH (2006) Local extravascular pool of C3 is a determinant of postischemic acute renal failure. FASEB J 20:217-2266
10. Fischer MB, Ma M, Goerg S, Zhou X, Xia J, Finco O, Han S, Kelsoe G, Howard RG, Rothstein TL, Kremmer E, Rosen FS, Carroll MC (1996) Regulation of the B cell response to T-dependent antigens by classical pathway complement. J Immunol 157:549-5566
11. Kerekes K, Prechl J, Bajtay Z, Jozsi M, Erdei A (1998) A further link between innate and adaptive immunity: C3 deposition on antigen-presenting cells enhances the proliferation of antigen-specific T cells. Int Immunol 10:1923-19300
12. Keslar K, Rodriguez ER, Tan CD, Starling RC, Heeger PS (2008) Complement gene expression in human cardiac allograft biopsies as a correlate of histologic grade of injury. Transplantation 86:1319-13211
13. Lalli PN, Strainic MG, Yang M, Lin F, Medof ME, Heeger PS (2008) Locally produced C5a binds to T cell-expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis. Blood 112:1759-17666
14. Lechler RI, Sykes M, Thomson AW, Turka LA (2005) Organ transplantation - how much of the promise has been realized? Nat Med 11:605-6133
15. Lewis AG, Kohl G, Ma Q, Devarajan P, Kohl J (2008) Pharmacological targeting of C5a receptors during organ preservation improves kidney graft survival. Clin Exp Immunol 153:117-1266
16. Li K, Feito MJ, Sacks SH, Sheerin NS (2006) CD46 (membrane cofactor protein) acts as a human epithelial cell receptor for internalization of opsonized uropathogenic Escherichia coli . J Immunol 177:2543-25511
17. Li K, Sacks SH, Zhou W (2007) The relative importance of local and systemic complement production in ischaemia, transplantation and other pathologies. Mol Immunol 44:3866-38744
18. Li Q, Peng Q, Xing G, Li K, Wang N, Farrar CA, Meader L, Sacks SH, Zhou W (2010) Deficiency of C5aR prolongs renal allograft survival. J Am Soc Nephrol 21:1344-13533
19. Maraganore JM (1993) Pre-clinical and clinical studies on Hirulog: a potent and specific direct thrombin inhibitor. Adv Exp Med Biol 340:227-2366
20. Melchionna T, Karegli J, Farrar CA, McVey JH, Dorling A, Sacks SH, Smith RAG (2010) Integrating cytotopic strategy in transplantation: (1) Design of locally-acting coagulation inhibitors for use with anti-complement therapeutics. Mol Immunol 47(13):2203, Ref Type: Abstract
21. Naesens M, Li L, Ying L, Sansanwal P, Sigdel TK, Hsieh SC, Kambham N, Lerut E, Salvatierra O, Butte AJ, Sarwal MM (2009) Expression of complement components differs between kidney allografts from living and deceased donors. J Am Soc Nephrol 20:1839-18511
22. Pantazis P, Kalyanaraman VS, Bing DH (1990) Synthesis of the third component of complement (C3) by lectin-activated and HTLV-infected human T-cells. Mol Immunol 27:283-2899
23. Patel H, Smith RA, Sacks SH, Zhou W (2006) Therapeutic strategy with a membrane-localizing complement regulator to increase the number of usable donor organs after prolonged cold storage. J Am Soc Nephrol 17:1102-11111
24. Peng Q, Li K, Patel H, Sacks SH, Zhou W (2006) Dendritic cell synthesis of C3 is required for full T cell activation and development of a Th1 phenotype. J Immunol 176:3330-33411
25. Peng Q, Li K, Anderson K, Farrar CA, Lu B, Smith RA, Sacks SH, Zhou W (2008) Local production and activation of complement up-regulates the allostimulatory function of dendritic cells through C3a-C3aR interaction. Blood 111:2452-24611
26. Peng Q, Li K, Wang N, Li Q, Asgari E, Lu B, Woodruff TM, Sacks SH, Zhou W (2009) Dendritic cell function in allostimulation is modulated by C5aR signaling. J Immunol 183:6058-60688
27. Pratt JR, Hibbs MJ, Laver AJ, Smith RA, Sacks SH (1996) Effects of complement inhibition with soluble complement receptor-1 on vascular injury and in flammation during renal allograft rejection in the rat. Am J Pathol 149:2055-20666
28. Pratt JR, Basheer SA, Sacks SH (2002) Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med 8:582-5877
29. Pratt JR, Jones ME, Dong J, Zhou W, Chowdhury P, Smith RA, Sacks SH (2003) Nontransgenic hyperexpression of a complement regulator in donor kidney modulates transplant ischemia/reperfusion damage, acute rejection, and chronic nephropathy. Am J Pathol 163:1457-14655
30. Ricklin D, Lambris JD (2007) Complement-targeted therapeutics. Nat Biotechnol 25:1265-12755
31. Ricklin D, Lambris JD (2008) Compstatin: a complement inhibitor on its way to clinical application. Adv Exp Med Biol 632:273-2922
32. Rioux P (2001) TP-10 (AVANT Immunotherapeutics). Curr Opin Investig Drugs 2:364-3711
33. Roozendaal R, Carroll MC (2007) Complement receptors CD21 and CD35 in humoral immunity. Immunol Rev 219:157-1666
34. Schwaeble WJ, Lynch NJ, Clark JE, Marber M, Samani NJ, Ali YM, Dudler T, Parent B, Lhotta K, Wallis R, Farrar CA, Sacks S, Lee H, Zhang M, Iwaki D, Takahashi M, Fujita T, Tedford CE, Stover CM (2011) Targeting of mannanbinding lectin-associated serine protease-2 confers protection from myocardial and gastrointestinal ischemia/reperfusion injury. Proc Natl Acad Sci USA 108:7523-75288
35. Selander B, Martensson U, Weintraub A, Holmstrom E, Matsushita M, Thiel S, Jensenius JC, Truedsson L, Sjoholm AG (2006) Mannan-binding lectin activates C3 and the alternative complement pathway without involvement of C2. J Clin Invest 116:1425-14344
36. Smith RA (2002) Targeting anticomplement agents. Biochem Soc Trans 30:1037-10411
37. Smith RA, Dodd I, Oldroyd RG, Harry J, Clark C, Rolan P, Dawes L (2001) Preclinical and clinical progression of a membrane-targeted complement regulator therapeutic. Mol Immunol 38:122
38. Ref Type: Abstract Smith RAG, Koffman G, Chowdhury P, Smith KCG, Watson CJ, Nicholson ML, Zhou W, Sacks SH (2007) Membranelocalising complement inhibitors - clinical progress. Mol Immunol 44(16):3915
39. Ref Type: Abstract Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M, Halloran PF, Baldwin W, Ban fi G, Collins AB, Cosio F, David DS, Drachenberg C, Einecke G, Fogo AB, Gibson IW, Glotz D, Iskandar SS, Kraus E, Lerut E, Mannon RB, Mihatsch M, Nankivell BJ, Nickeleit V, Papadimitriou JC, Randhawa P, Regele H, Renaudin K, Roberts I, Seron D, Smith RN, Valente M (2008) Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 8:753-7600
40. Springall T, Sheerin NS, Abe K, Holers VM, Wan H, Sacks SH (2001) Epithelial secretion of C3 promotes colonization of the upper urinary tract by Escherichia coli . Nat Med 7:801-8066
41. Strainic MG, Liu J, Huang D, An F, Lalli PN, Muqim N, Shapiro VS, Dubyak GR, Heeger PS, Medof ME (2008) Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity 28:425-4355
42. Tang S, Sheerin NS, Zhou W, Brown Z, Sacks SH (1999a) Apical proteins stimulate complement synthesis by cultured human proximal tubular epithelial cells. J Am Soc Nephrol 10:69-766
43. Tang S, Zhou W, Sheerin NS, Vaughan RW, Sacks SH (1999b) Contribution of renal secreted complement C3 to the circulating pool in humans. J Immunol 162:4336-43411
44. Thurman JM, Ljubanovic D, Royer PA, Kraus DM, Molina H, Barry NP, Proctor G, Levi M, Holers VM (2006) Altered renal tubular expression of the complement inhibitor Crry permits complement activation after ischemia/reperfusion. J Clin Invest 116:357-3688
45. Weiser MR, Williams JP, Moore FD Jr, Kobzik L, Ma M, Hechtman HB, Carroll MC (1996) Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement. J Exp Med 183:2343-23488
46. Weisman HF, Bartow T, Leppo MK, Marsh HC Jr, Carson GR, Concino MF, Boyle MP, Roux KH, Weisfeldt ML, Fearon DT (1990) Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing postischemic myocardial in flammation and necrosis. Science 249:146-1511
47. Zhang M, Austen WG Jr, Chiu I, Alicot EM, Hung R, Ma M, Verna N, Xu M, Hechtman HB, Moore FD Jr, and Carroll MC (2004). Identi fication of a specific self-reactive IgM antibody that initiates intestinal ischemia/reperfusion injury. Proc Natl Acad Sci USA 101:38866
48. Zheng X, Feng B, Chen G, Zhang X, Li M, Sun H, Liu W, Vladau C, Liu R, Jevnikar AM, Garcia B, Zhong R, Min WP (2006) Preventing renal ischemia-reperfusion injury using small interfering RNA by targeting complement 3 gene. Am J Transplant 6:2099-21088
49. Zheng X, Zhang X, Feng B, Sun H, Suzuki M, Ichim T, Kubo N, Wong A, Min LR, Budohn ME, Garcia B, Jevnikar AM, Min WP (2008) Gene silencing of complement C5a receptor using siRNA for preventing ischemia/reperfusion injury. Am J Pathol 173:973-9800
50. Zhou W, Farrar CA, Abe K, Pratt JR, Marsh JE, Wang Y, Stahl GL, Sacks SH (2000) Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest 105:1363-13711
51. Zhou W, Patel H, Li K, Peng Q, Villiers MB, Sacks SH (2006) Macrophages from C3-de ficient mice have impaired potency to stimulate alloreactive T cells. Blood 107:2461-24699